2024
Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial
Jacobs J, Booth G, Stephens L, Tormey C, Adkins B. Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial. The Lancet 2024, 404: 433. PMID: 39097393, DOI: 10.1016/s0140-6736(24)01264-9.Peer-Reviewed Original Research
2008
Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response
Kenney B, Tormey CA. Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response. Platelets 2008, 19: 379-383. PMID: 18791945, DOI: 10.1080/09537100802082280.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAmputation, SurgicalAnti-Bacterial AgentsAntigens, Human PlateletAutoantibodiesBacteremiaCeftazidimeDrug Therapy, CombinationFoot DiseasesGram-Positive Bacterial InfectionsHumansImmunoglobulin GImmunoglobulin MImmunologic MemoryMaleMiddle AgedPurpura, Thrombocytopenic, IdiopathicSurgical Wound InfectionVancomycinConceptsAntibiotic therapyPlatelet antibodiesPlatelet countPlatelet destructionAdverse bleeding eventsAnamnestic antibody responseDrug-related thrombocytopeniaNew onset thrombocytopeniaRapid platelet destructionAnti-platelet antibodiesNormal platelet countCases of thrombocytopeniaSafe drug useBleeding eventsVancomycin administrationWet gangreneImmune thrombocytopeniaImmediate discontinuationRare complicationMale patientsAnamnestic responseDrug withdrawalSevere thrombocytopeniaAcute reductionPrior sensitization